Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zentalis Pharmaceuticals ( (ZNTL) ) has provided an announcement.
On May 12, 2026, Zentalis Pharmaceuticals reported first-quarter 2026 results and detailed progress in late-stage trials of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. The company selected a 400mg once-daily 5:2 dosing regimen as the pivotal monotherapy dose following favorable data from the DENALI Part 2a study, expanded DENALI to additional cohorts, and signaled a potential accelerated approval path, with topline results expected by year-end 2026.
The company also dosed the first patient in the ASPENOVA Phase 3 confirmatory trial comparing azenosertib to standard chemotherapy, advanced its MUIR combination program in ovarian cancer, and presented new preclinical and clinical data supporting pipeline expansion into other tumors. Zentalis ended March 31, 2026 with $211.8 million in cash and equivalents, projecting runway into late 2027 as it funds DENALI, ASPENOVA and related development and pre-commercialization activities.
The most recent analyst rating on (ZNTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.
Spark’s Take on ZNTL Stock
According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses, inconsistent revenue, and sustained cash burn, alongside shrinking equity). Offsetting factors include constructive technicals (positive MACD and price above longer-term moving averages) and favorable recent corporate events tied to advancing azenosertib into late-stage trials, while valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on ZNTL stock, click here.
More about Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing azenosertib, an investigational, oral, first-in-class WEE1 inhibitor. The company targets biomarker-selected patient populations, particularly Cyclin E1-positive platinum-resistant ovarian cancer, and is building commercial and diagnostic capabilities around this precision-medicine strategy.
Average Trading Volume: 1,961,299
Technical Sentiment Signal: Buy
Current Market Cap: $312.8M
For an in-depth examination of ZNTL stock, go to TipRanks’ Overview page.